Vaxxel — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vaxxel is a clinical-stage biotech developing intranasal live attenuated vaccines for respiratory infections, starting with a bivalent candidate for RSV and HMPV. The company's proprietary METAVAC® platform is based on a modified, non-pathogenic HMPV strain engineered to express antigens from multiple viruses, aiming to stimulate robust mucosal and systemic immunity. With a large addressable market in pediatric and elderly populations and a differentiated intranasal delivery approach, Vaxxel is positioned to address significant unmet needs in respiratory disease prevention. The company is currently in the preclinical/process development stage, advancing its lead candidate towards clinical trials.

Infectious DiseasesRespiratory Diseases

Technology Platform

METAVAC®: A proprietary, versatile viral vaccine platform based on a reverse-genetics, live attenuated Human Metapneumovirus (HMPV) vector. It is attenuated via deletion of the SH gene, designed to be intranasally administered, capable of expressing heterologous antigens (e.g., from RSV), and aims to induce robust mucosal and systemic immunity with a low inflammatory profile.

Opportunities

The primary opportunity is addressing the complete lack of a licensed vaccine for Human Metapneumovirus (HMPV), a major respiratory pathogen.

Furthermore, its intranasal, bivalent RSV-HMPV candidate could differentiate from recently launched injectable RSV vaccines by potentially offering easier administration, mucosal immunity, and protection against two viruses in one, targeting large pediatric and elderly populations.

Risk Factors

Key risks include the high clinical development risk of a novel live attenuated platform, potential safety concerns such as reversion to virulence or inadequate attenuation, and intense competition from large pharma companies with approved RSV products and vast resources.

The company also faces significant financing and execution risks inherent to an early-stage biotech.

Competitive Landscape

Vaxxel competes in the RSV prevention space with recently approved products from Pfizer (Abrysvo), GSK (Arexvy), and Sanofi (Beyfortus, a mAb). For HMPV, there are currently no approved vaccines, making it an open field. Competitors include large vaccine developers (e.g., Moderna, Janssen) and other biotechs exploring HMPV vaccines, but Vaxxel's intranasal bivalent approach is a key differentiator.

More companies in Biologics / Biosimilars →More companies in France →